Objective-IL-35 (interleukin-35) is an anti-inflammatory cytokine, which inhibits immune responses by inducing regulatory T cells and regulatory B cells and suppressing effector T cells and macrophages. It remains unknown whether atherogenic stimuli induce IL-35 and whether IL-35 inhibits atherogenic lipid-induced endothelial cell (EC) activation and atherosclerosis. EC activation induced by hyperlipidemia stimuli, including lysophosphatidylcholine is considered as an initiation step for monocyte recruitment and atherosclerosis. In this study, we examined the expression of IL-35 during early atherosclerosis and the roles and mechanisms of IL-35 in suppressing lysophosphatidylcholine-induced EC activation. Approach and Results-Using microarray and ELISA, we found that IL-35 and its receptor are significantly induced during early atherosclerosis in the aortas and plasma of ApoE (apolipoprotein E) knockout mice-an atherosclerotic mouse modeland in the plasma of hypercholesterolemic patients. In addition, we found that IL-35 suppresses lysophosphatidylcholineinduced monocyte adhesion to human aortic ECs. Furthermore, our RNA-sequencing analysis shows that IL-35 selectively inhibits lysophosphatidylcholine-induced EC activation-related genes, such as ICAM-1 (intercellular adhesion molecule-1). Mechanistically, using flow cytometry, mass spectrometry, electron spin resonance analyses, and chromatin immunoprecipitation-sequencing analyses, we found that IL-35 blocks lysophosphatidylcholine-induced mitochondrial reactive oxygen species, which are required for the induction of site-specific H3K14 (histone 3 lysine 14) acetylation, increased binding of proinflammatory transcription factor AP-1 in the promoter of ICAM-1, and induction of ICAM-1 transcription in human aortic EC. Finally, IL-35 cytokine therapy suppresses atherosclerotic lesion development in ApoE knockout mice. Conclusions-IL-35 is induced during atherosclerosis development and inhibits mitochondrial reactive oxygen species-H3K14 acetylation-AP-1-mediated EC activation. Visual Overview-An online visual overview is available for this article. into various Th functional subsets, including Th1, Th2, Th17, Th9, Th22, follicular Th, and Tregs. 17 The majority of Th cell functions are fulfilled via the secretion of various cytokines, which can play a dual role in regulating atherogenesis. 18 Proinflammatory and Th1-related cytokines, such as IL-1 (interleukin-1), promote the development and progression of atherosclerosis. 19, 20 However, Tregs-related anti-inflammatory cytokines, such as IL-10 and TGF-β (transforming growth factor-β), exert clear antiatherogenic activities. 21, 22 Recently, IL-35 has been identified as a novel immunosuppressive/anti-inflammatory cytokine.
C ardiovascular disease (CVD) remains a leading cause of fatality in well-developed countries. As a chronic autoimmune inflammatory disease, atherosclerosis involves both the innate and adaptive arms of the immune response that mediate the initiation, progression, and ultimate thrombotic complications of atherosclerosis. 1 We and others have reported that hyperlipidemia, along with other CVD stressors, such as hyperglycemia, chronic kidney disease, obesity, and hyperhomocysteinemia, promote atherosclerosis via several mechanisms. These mechanisms include endothelial cell (EC) activation and injury, [2] [3] [4] [5] monocyte recruitment and differentiation, 6, 7 decreased regulatory T cells (Tregs), [8] [9] [10] impaired vascular repair ability of bone marrow-derived progenitor cells, [11] [12] [13] increased migration and proliferation of vascular smooth muscle cells, 14, 15 and high fat-induced adipocyte hypertrophy. 16 However, the underlying mechanisms of how Tregs inhibit vascular response during atherosclerosis remain not fully understood. CD4 + T helper cells (Th) play essential roles in regulating inflammation and immune responses via differentiation into various Th functional subsets, including Th1, Th2, Th17, Th9, Th22, follicular Th, and Tregs. 17 The majority of Th cell functions are fulfilled via the secretion of various cytokines, which can play a dual role in regulating atherogenesis. 18 Proinflammatory and Th1-related cytokines, such as IL-1 (interleukin-1), promote the development and progression of atherosclerosis. 19, 20 However, Tregs-related anti-inflammatory cytokines, such as IL-10 and TGF-β (transforming growth factor-β), exert clear antiatherogenic activities. 21, 22 Recently, IL-35 has been identified as a novel immunosuppressive/anti-inflammatory cytokine. 23 IL-35 is a dimeric protein with 2 subunits: IL-35A and EBI3 (EpsteinBarr virus induced 3). 24, 25 IL-35 is secreted by Tregs, regulatory B cells, 26 dendritic cells, 27 and to less extent by ECs, smooth muscle cells, and monocytes. 28 We have reported previously that in contrast to another immunosuppressive cytokine TGF-β, IL-35 is not constitutively expressed in tissues but rather induced by proinflammatory stimuli 23, 29 and inhibits lipopolysaccharide-induced EC activation 29 and that IL-35 is a newly proposed homeostasis-associated molecular pattern. 30 However, an important issue of whether IL-35 is induced during chronic atherogenesis development remains unknown.
Lysophosphatidylcholines are a group of bioactive, proinflammatory lipid molecules and a newly proposed conditional danger-associated molecular pattern, 31 which are critically involved in the development of atherosclerosis. 32 It has been suggested that lysophosphatidylcholineinduced EC activation is an initiation step of atherogenesis. 4 During early hyperlipidemia, lysophosphatidylcholines are induced and activate EC to produce adhesion molecules, such as ICAM-1 (intercellular adhesion molecule-1), which mediate the adhesion and migration of leukocyte into the intima, 33 contributing to atherosclerosis development. We have shown previously that IL-35 could inhibit lipopolysaccharide-induced EC activation process during acute inflammatory responses in sepsis. 29 However, the issues of whether IL-35 could suppress hyperlipidemia stimuli-induced EC activation during chronic inflammation and by what mechanisms IL-35 suppresses EC activation remain unclear.
Epigenetic regulations in the cell include DNA methylation, noncoding RNAs, and post-translational modification of histone proteins, such as acetylation, methylation, phosphorylation, ubiquitylation, and SUMOylation. [34] [35] [36] Key posttranslational modifications of histones include methylation and acetylation. 35 Histone acetylation favors gene transcription and is considered as a hallmark of transcriptionally active regions. The addition of acetyl groups on histone tails facilitates gene transcription by neutralizing the histone charges, thus weakening histone-DNA interaction, relaxing the chromatin structure, and allowing related transcription factors to bind to gene promoters. 37 It has been shown that proatherogenic stimuli oxidized low-density lipoprotein induces histone 3 (H3) and H4 acetylation globally, which contributes to EC activation by upregulating IL-8 and MCP-1 (monocyte chemoattractant protein-1/CCL2) expression. 38 However, because there are at least 12 histone acetylation sites in the H3 histone tails alone, 36 it remains unknown whether site-specific histone acetylation events contribute to hyperlipidemia-induced EC activation.
Thus, despite significant progress, several important knowledge gaps exist: First, the expression profile of IL-35 in atherosclerosis remains unknown; and second, the roles and detailed molecular mechanisms of IL-35 in hyperlipidemic stimuli-induced aortic EC activation and atherogenesis development are unclear. In this study, we hypothesized that IL-35 is induced during atherosclerosis development and plays an antiatherosclerosis role. Using RNA sequencing, chromatin immunoprecipitation sequencing, mass spectrometry, electron spin resonance, and several other biochemical assays, we found that IL-35 is an atherosclerosis-induced anti-inflammatory cytokine, which inhibits hyperlipidemic stimuli-induced EC activation and atherosclerosis. Moreover, we identified a novel mitochondrial reactive oxygen species (mtROS)-driven site-specific H3K14 (histone 3 lysine 14) acetylation mechanism in driving EC activation gene transcription, which could be suppressed by IL-35. Thus, a previously uncharacterized novel pathophysiological pathway linking 3 dots, including endogenous metabolite danger signal lysophosphatidylcholine as we proposed, 31, 39 mitochondria-derived metabolites (mtROS), and nucleus signaling, is uncovered, which is important for hyperlipidemia-induced EC activation. Our indepth analysis of the roles of IL-35 in suppressing EC activation and atherosclerosis development has provided novel avenues for therapeutic treatments for vascular inflammation and other CVDs.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement. We have shown previously that IL-35 is a responsive antiinflammatory cytokine, which is induced in several vascular cell types in response to inflammatory cytokine stimulation and during acute inflammatory response in endotoxemia. 23, 29, 30 In this study, we hypothesized that IL-35 is also induced in the development of atherosclerosis, which is a chronic inflammatory disease. To test this hypothesis, first, we examined the gene expression of IL-35 and its receptor in the aortas of ApoE −/− (apolipoprotein E knockout) mice in comparison with those of WT (wild-type) mice using microarray analysis ( Figure 1A ). It has been reported that the engagement of IL-35 with different receptor subunits depends on the cell type studied 30, 40 ( Figure 1B) . Regardless of the receptor composition, our results showed that both IL-35 subunits (Il35a and Ebi3) and all the potential IL-35 receptor subunits are significantly induced in the aortas of ApoE −/− mice in comparison , n=4). E, Plasma cholesterol levels were measured in the plasma samples from same patients (n=8) and healthy controls (n=15). F, The ELISA was performed for the detection of human IL-35 in the plasma samples from patients with hypercholesterolemia (n=7) and healthy controls (n=15). G, Positive correlation between plasma cholesterol levels and IL-35 levels (simple linear regression analysis) in patient samples. For all panels, data are expressed as mean±SEM. *P<0.05, **P<0.01, ***P<0.001. EBI3 indicates Epstein-Barr virus induced 3.
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with those of WT mice ( Figure 1C ). Notably, IL-35 receptor subunit IL35rb2 was highly induced when comparing with the IL-35 itself, indicating that the aorta tissue is a target rather than a source of IL-35 during early atherosclerosis development. This result is supported by the findings of increased IL-35 levels in the plasma of ApoE −/− mice fed with either chow diet or high-fat diet, compared with those of WT mice ( Figure 1D ). We also examined IL-35 protein expression in the plasma samples from patients with hypercholesterolemia and healthy controls, as judged by their plasma cholesterol concentrations ( Figure 1E ). We found that the levels of IL-35 are significantly induced in the hypercholesterolemic patients and that increased IL-35 levels are positively correlated with cholesterol concentrations ( Figure 1F and 1G). Taken together, these results suggest that hyperlipidemia conditions upregulate IL-35 cytokine expressions in the blood, which could then signal in the aortic cells by heightened IL-35 receptor expression.
IL-35 Suppresses Proatherogenic Lysophosphatidylcholine-Induced Human Aortic EC Activation by Inhibiting ICAM-1 Expression
Next, we hypothesized that IL-35 could inhibit lysophosphatidylcholine-induced EC activation process, which is an initiation step of atherogenesis. The results showed that IL-35 could completely abolish nonstimulated human peripheral blood monocyte adhesion to lysophosphatidylcholine-treated human aortic ECs (HAECs; Figure 2A ). The results allowed us to argue that IL-35 could inhibit lysophosphatidylcholineinduced EC activation by inhibiting the gene expression of adhesion molecules and chemokines/cytokines. To test this hypothesis, we performed RNA-sequencing experiments using the following 3 RNA samples, including (1) control HAECs, (2) HAECs stimulated with lysophosphatidylcholine, and (3) HAECs stimulated with lysophosphatidylcholine and IL-35. We found that among the genes that were significantly induced by lysophosphatidylcholine in HAECs, IL-35 could significantly inhibit the expression of 10 genes, including IGFBP5 (insulin-like growth factor-binding protein 5), CAPN3 (calpain 3), TRAF1 (tumor necrosis factor receptor-associated factor 1), CDRT4 (CMT1A duplicated region transcript 4), IL-1B, TGF-β3, NF-kB subunit RELB, CXCL (chemokine [C-X-C motif] ligand) 1, ICAM-1, and CXCL8 ( Figure 2B ; Tables I and II in the online-only Data Supplement). Strikingly, the ingenuity pathway analysis revealed that arrest in movement of cells is the most significantly enriched pathway, with 4 of these 10 IL-35-inhibited genes in this pathway (P=1.02E-10; Figure 2C ; Table III in the online-only Data Supplement). Using EC adhesion molecule ICAM-1 as prototype for lysophosphatidylcholineinduced but IL-35-suppressed EC activation molecules, we performed both RT-PCR and Western blots and confirmed that IL-35 significantly inhibited lysophosphatidylcholineinduced ICAM-1 RNA and protein expression ( Figure 2D and 2E). Taken together, these results strongly support the notion that IL-35 suppresses lysophosphatidylcholine-induced EC activation by inhibiting EC activation-related genes, such as ICAM-1.
IL-35 Suppresses LysophosphatidylcholineInduced mtROS, Which Are Required for Site-Specific Histone Acetylation of H3K14
EC activation process is accompanied by massive chromatin remodeling process, which is required for the stable transcriptional induction of EC activation-related gene expression. 41 Histone acetylation favors gene transcription and is considered as a hallmark of transcriptionally active regions. The addition of acetyl groups on histone tails was considered to facilitate gene transcription by neutralizing the histone charges, thus weakening histone-DNA interaction and relaxing the chromatin structure. 36, 37 Our recent report showed that among 164 histone modification enzymes in ApoE −/− mouse aortas, atherosclerosis downregulated as many as 8 HDACs (histone deacetylases), upregulated only 1 HAT (histone acetyltransferase) 1, but none of HDACs, suggesting that in atherogenic process, site-specific histone acetylation may be a major event. 36 Thus, we hypothesized that during EC activation process elicited by hyperlipidemia stimulation lysophosphatidylcholine, chromatin remodeling of EC activation genes, such as ICAM-1, occurs presumably via increased HAT-mediated specific histone acetylation, which could be inhibited by IL-35. To test this hypothesis, we applied site-specific histone acetylation screening by high-performance liquid chromatography coupled with mass spectrometer method 42, 43 ( Figure 3A ). We screened for 8 different lysine acetylation positions on histone H3, including lysine 9 (K9), K14, K18, K23, K27, K36, K37, and K64 simultaneously ( Figure IA in the online-only Data Supplement). The results showed that lysophosphatidylcholine treatment (10 μM) for 2 hours specifically induces H3K14 acetylation (H3K14ac) in HAECs in a dose-and timedependent manner ( Figure 3B ) and to a lesser degree, H3K23 acetylation ( Figure IB in the online-only Data Supplement). The acetylation levels of H3K9 and H3K18 were not significantly changed by lysophosphatidylcholine treatment, and the acetylation levels of K27, K36, K37, and K64 did not reach the detection limits and were not plotted.
It has been reported previously that mitochondria serve as upstream regulators of global histone acetylation by providing the substrate in the form of acetyl-coA 44 ( Figure 3C ). Because we have reported previously that mtROS 45 mediate lysophosphatidylcholine-induced EC activation, 4 we hypothesized that mitochondria-derived mtROS signaling provides additional layer of histone regulation by site-specific regulation of histone H3 ( Figure 3C ). We found that lysophosphatidylcholine dose dependently increases mtROS in HAEC, as we have reported previously 4 ( Figure 3D) . Importantly, the induction of mtROS was positively associated with the induction of H3K14ac but not H3K18ac or H3K23ac (Figure 3E through 3G). To consolidate these findings, we used 2 different methods, Western blots and electron spin resonance, to simultaneously measure H3K14ac and mtROS, respectively, in the same group of cells. Similar to the results obtained from the analyses of mass spectrum and flow cytometry, we found that lysophosphatidylcholine could significantly induce H3K14ac and mtROS in HAECs ( Figure 3H and 3I) and that the induction of mtROS was positively associated with H3K14ac increase ( Figure 3J ). Furthermore, when mtROS inhibitor MitoTEMPO is applied, lysophosphatidylcholine-induced H3K14ac is inhibited ( Figure 3K ), suggesting that mtROS is located upstream of the histone H3 acetylation, and specifically mediates lysophosphatidylcholine-induced H3K14ac. Remarkably, IL-35 could completely inhibit lysophosphatidylcholine-induced mtROS and H3K14ac ( Figure 3L and 3M), suggesting that inhibition of H3K14ac by IL-35 probably acts via suppressing lysophosphatidylcholine-induced mtROS first. Collectively, we unveiled a new mitochondria-tonucleus communication pathway during EC activation, which could be blocked by IL-35.
Lysophosphatidylcholine-Induced H3K14ac Is Required for ICAM-1 Gene Expression by Increasing the Accessibility of AP-1, Which Is Inhibited by IL-35
Next, we hypothesized that H3K14ac induced by lysophosphatidylcholine may result in increased binding of H3K14ac to specific EC activation-related areas in HAEC genomic DNAs. To test this hypothesis, we performed chromatin immunoprecipitation sequencing of H3K14ac in HAECs treated with vehicle or lysophosphatidylcholine ( Figure 4A ). The results showed that lysophosphatidylcholine further induces both stronger and wider H3K14ac signals in the promoter and enhancer regions of ICAM-1, whereas there are weak H3K14ac signals in the ICAM-1 promoter region under basal conditions ( Figure 4B ). In addition, because we reported that atherosclerosis specifically upregulates HAT expression, 36 when HAT inhibitor curcumin (which blocks histone acetylation) was applied, the induction of ICAM-1 by lysophosphatidylcholine was abolished ( Figure 4C ), suggesting that HAT-mediated H3K14ac is responsible for lysophosphatidylcholine-increased ICAM-1 upregulation.
We have shown previously that transcription factor AP-1 mediated lysophosphatidylcholine-induced EC activation. 4 In addition, among the 10 genes that are suppressed by IL-35 in lysophosphatidylcholine-treated HAECs, 3 of them were previously predicted to be the downstream targets of AP-1 pathway by ingenuity pathway analysis ( Figure 4D ). Besides, we have shown previously that AP-1 mediates lysophosphatidylcholine-induced EC activation. 4 Thus, we further hypothesized that lysophosphatidylcholine-induced H3K14ac contributes to ICAM-1 upregulation and EC activation by promoting the accessibility of AP-1 to ICAM-1 promoter, which was inhibited by IL-35. Using electrophoretic mobility shift assay, we found that HAT inhibitor curcumin, which blocks H3K14ac, completely abolished AP-1 binding to the ICAM-1 promoter AP-1 site in HAEC DNAs. Moreover, IL-35 also inhibited (1 h/2 h), histones were purified. After propionylation and trypsin digestion, the acetylation fractions on individual lysine residues on histone H3 were measured by high-performance liquid chromatography coupled with MS method. C, Working model of communications between mitochondria and nucleus through means of mtROS and acetyl-CoA. D, After loading with MitoSOX (5 μM) for 10 min, HAECs were treated with LPC (10 μM; 16:0) for different doses for 1 h, and flow cytometry analysis was performed to quantify mtROS (n=3). E-G, Correlation analyses between mtROS and site-specific histone acetylation from the data of (B and D). H, HAECs were treated with LPC (10 μM) for 2 h, and protein was collected for Western blot analysis. Quantification was shown in the (right; n=3). I, Aliquots from the same samples from (H) were also used to measure mtROS by electron spin resonance by MitoTEMPO-H. Quantification was shown in the (right; n=3). J, Correlation analyses between mtROS and site-specific histone acetylation from the data of (H and I). K, HAECs were treated with LPC (10 μM) or LPC (10 μM) plus MitoTEMPO-H (1 μM) for 2 h, and protein was collected for Western blot analysis. 
IL-35 Inhibits the Development of Atherosclerosis in ApoE −/− Mice
Finally, we hypothesized that IL-35 cytokine therapy could suppress atherosclerosis, at least in part, because of inhibition of hyperlipidemic stimuli-promoted EC activation in -35) . A, Principle of CHIP sequencing of H3K14ac. B, After treatment of vehicle or LPC (10 μM) for 2 h, chromatins were collected, cross-linked, and sheared. Immunoprecipitation of H3K14ac was performed afterward, and the resulting coimmunoprecipitated DNA regions were purified, sequenced, and aligned to human genome (hg19). Unprecipitated chromatin sample was used for input control. Data were visualized using UCSC (University of California, Santa Cruz) genome browser. Blue bars indicate significant difference between control and input, and red bars indicate significant difference between LPC and control. Pooled samples in each group (n=5). C, Human aortic endothelial cells (HAECs) were treated with LPC (10 μM) with or without curcumin (10 μM) for 18 h, and protein was collected for Western blot analysis. D, AP-1 is predicted to be the upstream regulator of IL-35-regulated genes by ingenuity pathway analysis. E, HAECs were treated with LPC (10 μM) with or without curcumin (10 μM) for 1 h, and electrophoretic mobility shift assay (EMSA) of AP-1 was performed. F, HAECs were treated with LPC (10 μM) with/without IL-35 (10 ng/mL) for 1 h, and EMSA was performed. G, A new working model of how LPC inhibits LPC-induced H3K14ac and AP-1 binding to the promoter of ICAM-1. IP indicates immunoprecipitation. ApoE −/− mice. To test this hypothesis, we adopted a reported method of cytokine therapy for atherosclerosis. 46 Our results showed that intraperitoneal injection of mouse IL-35, 3× per week ( Figure 5A ) for the last 5 weeks of 11-week high-fat diet-feeding period, significantly inhibited atherosclerosis development in ApoE −/− mice fed with high-fat diet ( Figure 5B through 5E). These data correlated well with a recent report, which showed similar results, 47 and suggested that pharmacological inhibition of endothelial activation and atherosclerosis by IL-35 could be developed into potential therapeutics against atherosclerosis development.
Discussion
Atherosclerosis is a chronic inflammatory autoimmune disease, which is a major pathogenic process underlying the development of coronary heart disease, stroke, and peripheral vascular disease. Despite of our improved understanding of the critical role the immune system in atherosclerosis, 48 current anti-inflammatory strategies are not clinically effective in the prevention and treatment of atherosclerotic CVD. 49 We reported previously that IL-35 is a responsive anti-inflammatory cytokine upregulated during inflammatory response but not a constitutively expressed house-keeping cytokine. 23 In addition, we also reported that IL-35 is induced in endotoxemia, and it inhibits endotoxin-induced acute vascular inflammation. 29 In the current study, we investigated the role and molecular mechanisms underlying IL-35 in suppressing aortic endothelial activation and atherosclerosis. We have made the following findings: (1) IL-35 is upregulated during early and advanced atherosclerosis in human and mouse plasma, and the expressions of IL-35 receptor transcripts are upregulated in atherogenic ApoE −/− mouse aortas, suggesting that IL-35 is also an inflammation-responsive cytokine in atherosclerosis; (2) IL-35 suppresses the adhesion of nonstimulated primary human monocytes to lysophosphatidylcholine-treated HAECs, suggesting IL-35 inhibition of endothelial activation; (3) global transcriptomic analyses reveal that IL-35 suppresses HAEC activation by inhibiting the expression of EC activationrelated molecules, including ICAM-1; (4) mass spectrometric analysis of histone acetylation suggests that among 8 potential histone 3 (H3) potentially acetylated lysine (K) positions, including K9, K14, K18, K23, K27, K36, K37, and K64, lysophosphatidylcholine epigenetically regulates EC activation by specifically inducing H3K14ac, which is inhibiting by IL-35; (5) the results from chromatin immunoprecipitation-sequencing experiment indicate that lysophosphatidylcholine-induced H3K14ac contributes to ICAM-1 upregulation by increasing AP-1 accessibility to ICAM-1 promoter, which is suppressed by IL-35; and (6) treatment of ApoE −/− mice with IL-35 cytokine significantly inhibits atherosclerosis development, presumably partially by inhibiting endothelial activation.
Previous studies have shown that mitochondria could communicate with the nucleus and globally regulate histone acetylation events by providing the substrates for HATs in the form of acetyl-CoA. 44 Nevertheless, site-specific histone acetylation regulation by the mitochondria must exist to regulate specific epigenetic events. To our knowledge, our study is the first report to indicate that mitochondria, in the form of mtROS, could specifically remodel the chromatin architecture in EC activation by contributing to site-specific histone acetylation events. Thus, mitochondria could both globally regulate histone acetylation by regulating the levels of acetyl-CoA and fine-tune specific histone events by signaling through mtROS ( Figure 3C ).
As we recently analyzed, histone acetylation is regulated by orchestrated effects of 31 HATs and 18 HDACs, 36 which work either by themselves or cooperatively to acetylate/ deacetylate specific site(s) on histones. Nevertheless, such histone codes remain not fully understood, and we speculate that lysophosphatidylcholine-induced mtROS might regulate the activity of certain histone modification enzymes. This notion was supported by our recent data mining report, which analyzed the expressions of 164 histone modification enzymes and showed that in metabolic diseases, including atherosclerosis, the expressions of most HDACs are downregulated, whereas only 1 HAT1 is upregulated, suggesting a role of sitespecific histone acetylation in atherogenesis. 36 Future experiments in characterizing the specific roles of different histone acetylation enzymes in EC activation and atherosclerosis are warranted.
Our results for the first time demonstrated that IL-35 can suppress EC activation by inhibiting mtROS generation. Since mtROS also contribute to inflammatory cytokine production and innate immune responses in macrophages and T cells [50] [51] [52] besides mediating aortic EC activation, 4 it would be interesting to examine whether the proposed pathway holds true in these immune cells in the future. As we pointed out previously, mtROS levels are determined by the rates of both mtROS production and disposal. 45 Several factors can also regulate mtROS levels, including (1) mitochondrial membrane potential ΔΨm; (2) metabolic state of mitochondria; (3) O 2 concentration and mitochondrial mass; (4) mitochondrial fusion; (5) transcription factors p53 and STAT3; (6) class III NAD+ (nicotine adenine dinucleotide)-dependent deacetylases, including sirtuin 1 2 ; (7) cytokines, including TNF-α; and (8) non-mtROS sources. 53 In addition, our new article reported that lysophosphatidylcholine-induced, ATP synthesis-uncoupled mitochondrial proton leak and calcium influx promote mtROS generation. 4, 5 Thus, future studies also need to address whether IL-35 specifically modulate some, if not all, of these mtROS-regulating factors to inhibit mtROS and whether other anti-inflammatory cytokines, such as IL-10 and TGF-β, could inhibit mtROS.
STAT3, initially identified as a transcription factor that regulates gene expression in response to cytokines, such as IL-6 and IL-10, has recently been found to modulate mtROS through mechanisms independent of its nuclear factor activity but dependent on its ability to directly modulate the activity of the electron transport chain. 54, 55 It has been shown that STAT3 is present in the mitochondrial matrix, and deficiency of STAT3 in murine hearts leads to decreased activities of complexes I and II while increasing mtROS at complex I. 55 Because STAT3 serves as downstream signaling molecule of IL-35, it is tempting to speculate that IL-35-induced STAT3 might talk to the mitochondria to suppress mtROS production. By modulating mitochondrial electron transport chain activity and mtROS generation, STAT3 could link IL-35 signaling pathway to cellular metabolism. We are in the process to examine this potential.
To summarize, we propose a new working model of mtROS-H3K14ac-mediated EC activation as IL-35 targeted pathway: (1) atherogenesis not only upregulates proatherogenic factors but also increases antiatherogenic factors, including IL-35, suggesting that IL-35 serves as an important homeostasis-maintaining regulator. However, such protective mechanism from IL-35 eventually fails as hyperlipidemia condition worsens and overcomes the protection. Thus, we think that exogenous supplementation of IL-35 is a feasible approach in the treatment of CVDs similar to a recent report on CANTOS trial (The Canakinumab Anti-inflammatory Thrombosis Outcomes Study) with anti-IL-1β antibody canakinumab 56 and that combinational anti-inflammatory therapies might result in even better outcome against CVD; (2) mtROS generation is an upstream target for IL-35 suppression of mtROS-H3K14ac-AP-1-ICAM-1-mediated endothelial activation; and (3) as a prototypic conditional DAMP that we reported recently, 31 lysophosphatidylcholine-induced EC activation is mediated by potentially nonspecific mtROS followed by highly specific H3K14ac pathway. Our results are supported by a recently published article, which reported that IL-35 could inhibit atherosclerosis by enhancing Tregmediated immune suppression. 47 We think that IL-35 plays an antiatherogenic role by targeting multiple cell types, including ECs and Tregs. Additional experiments that dissect the precise mechanisms of IL-35-dependent regulation of antiatherogenic response are needed, and this could eventually lead to identification of novel therapeutic targets for suppressing endothelial activation and atherosclerosis ( Figure 6 ). 
